Polyneuropathy

Classification

Polyneuropathies may be classified in different ways, such as by cause,

• Distal axonopathy, is the result of interrupted function of the peripheral nerves. It is the most common response of neurons to metabolic or toxic disturbances, and may be caused by metabolic diseases such as diabetes, kidney failure, connective tissue disease, deficiency syndromes such as malnutrition and alcoholism, or the effects of toxins or drugs such as chemotherapy. They may be divided according to the type of axon affected (large-fiber, small-fiber, or both). The most distal portions of axons are usually the first to degenerate, and axonal atrophy advances slowly toward the nerve's cell body. However, if the cause is removed, then regeneration is possible, although the prognosis depends on the duration and severity of the original stimulus. People with distal axonopathies usually present with sensorimotor disturbances such as amyotrophic lateral sclerosis.
• Myelinopathy, is due to a loss of myelin or of the Schwann cells. This demyelination slows down or completely blocks the conduction of action potentials through the axon of the nerve cell (neurapraxia). The most common cause is acute inflammatory demyelinating polyneuropathy AIDP, the most common form of Guillain–Barré syndrome (although other causes include chronic inflammatory demyelinating polyneuropathy).
• Neuronopathy is the result of issues in the peripheral nervous system (PNS) neurons. They may be caused by motor neurone diseases, sensory neuronopathies, toxins, or autonomic dysfunction. Neurotoxins such as chemotherapy agents may cause neuronopathies.

Signs and symptoms

Among the signs and symptoms of polyneuropathy, which can be divided (into sensory and hereditary) and are consistent with the following, are:

• Sensory polyneuropathy – ataxia, numbness, muscle wasting and paraesthesiae.
• Hereditary polyneuropathy – scoliosis and hammer toes

Causes

The causes of polyneuropathy can be divided into hereditary and acquired and are therefore as follows:

• Inherited – hereditary motor neuropathies, Charcot–Marie–Tooth disease, and hereditary neuropathy with liability to pressure palsy
• Acquired – diabetes mellitus, vascular neuropathy, alcohol use disorder, vitamin E deficiency, and vitamin B12 deficiency

Pathophysiology

The pathophysiology of polyneuropathy depends on the type. Chronic inflammatory demyelinating polyneuropathy, for instance, is an autoimmune disease: T cells involvement has been demonstrated, antibodies alone are not capable of demyelination.

Diagnosis

The diagnosis of polyneuropathy begins with a history (anamnesis) and physical examination to ascertain the pattern of the disease process (such as arms, legs, distal, proximal), if they fluctuate, and what deficits and pain are involved. If pain is a factor, determining where and how long it has been present is important; one also needs to know what disorders are present within the family and what diseases the person may have. Although diseases often are suggested by the physical examination and history alone, tests that may be employed include electrodiagnostic testing, serum protein electrophoresis, nerve conduction studies, urinalysis, serum creatine kinase (CK) and antibody testing; nerve biopsy is done sometimes.

Other tests may be used, especially tests for specific disorders associated with polyneuropathies; quality measures have been developed to diagnose patients with distal symmetrical polyneuropathy (DSP).

Differential diagnosis

In terms of the differential diagnosis for polyneuropathy, the following must be considered:

• Vitamin deficiency
• Diabetes mellitus
• Toxins
• Guillain–Barré syndrome
• Lyme disease
• Hepatitis C
• Amyloidosis
• Acromegaly
• Kidney failure
• Friedreich's Ataxia

Treatment

In the treatment of polyneuropathies one must ascertain and manage the cause, among management activities are: weight decrease, use of a walking aid, and occupational therapist assistance. Additionally, BP control in those with diabetes is helpful, while intravenous immunoglobulin is used for multifocal motor neuropathy.

According to Lopate, et al., methylprednisolone is a viable treatment for chronic inflammatory demyelinative polyneuropathy (which can also be treated with intravenous immunoglobulin). The authors also indicate that prednisone has greater adverse effects in such treatment, as opposed to intermittent (high-doses) of the aforementioned medication.

According to Wu, et al., in critical illness polyneuropathy supportive and preventive therapy are important for the affected individual, as well as, avoiding (or limiting) corticosteroids.

References

References

1. "Polyneuropathies. Medical information about polyneuropathy {{!}} Patient".
2. Richard A C Hughes. (23 February 2002). "Clinical review: Peripheral neuropathy". British Medical Journal.
3. (21 April 2010). "Patient page: Peripheral neuropathy". Journal of the American Medical Association.
4. (19 September 2012). "Peripheral neuropathy fact sheet". National Institute of Neurological Disorders and Stroke.
5. (2015-02-02). "Textbook of Family Medicine". Elsevier Health Sciences.
6. (2014-01-30). "Pathophysiology: The Biologic Basis for Disease in Adults and Children". Elsevier Health Sciences.
7. (2007). "The chemotherapy source book". Lippincott Williams & Wilkins.
8. (14 August 2014). "ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease". Frontiers in Neuroscience.
9. (2008). "Clinical neurology". Manson.
10. (2013-08-07). "Pathology: Implications for the Physical Therapist". Elsevier Health Sciences.
11. RESERVED, INSERM US14 – ALL RIGHTS. "Orphanet: Acute inflammatory demyelinating polyradiculoneuropathy".
12. "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Information Page: National Institute of Neurological Disorders and Stroke (NINDS)".
13. (May 2013). "Pattern-Recognition Approach to Neuropathy and Neuronopathy". Neurologic Clinics.
14. (2014-11-25). "Physical Medicine and Rehabilitation Board Review, Third Edition". Demos Medical Publishing.
15. (1 January 2010). "Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins". Biologics: Targets and Therapy.
16. (15 February 2011). "The Evaluation of Polyneuropathies". Neurology.
17. (13 May 2014). "Quality improvement in neurology". Neurology.
18. "Polyneuropathy/differential diagnosis". BMJ Best Practices.
19. [https://www.medlineplus.gov/ency/article/000471.htm Chronic renal failure] , ''Medline Plus''
20. (2013). "Friedreich Ataxia: Neuropathology Revised". Journal of Neuropathology & Experimental Neurology.
21. (1 January 2014). "Critical illness polyneuropathy and myopathy: a systematic review". Neural Regeneration Research.